Evidence map›Paper›PMID 20132098›Full record

ReviewClinical science (London, England : 1979)2010

Cellular and molecular biology of Neisseria meningitidis colonization and invasive disease.

Darryl J Hill, Natalie J Griffiths, Elena Borodina, Mumtaz Virji

Registry-linked trialOpen access · bronzeAbstract readReview
In one paragraph

Review in Clinical science (London, England : 1979), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01766206 (A Multicenter Post Marketing Surveillance Study to Monitor the Safety of GlaxoSmithKline), which is not on this map. Cited by 98 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 1 pooled it
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01766206 phase4completednot on this mapstarted 2013, after this paper: background citation

A Multicenter Post Marketing Surveillance Study to Monitor the Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ACWY Conjugate Vaccine(MenACWY-CRM) Administered According to the Prescribing Information to Healthy Subjects From 2 Months to 55 Years of Age in the Republic of South Korea.

TypeinterventionalSponsorGlaxoSmithKlineRan2013 to 2018Enrolled3,948ConditionsMeningococcal DiseaseArmsMenACWY-CRM (Menveo)
3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 1 synthesis or guideline pooled it, 186 citations in OpenAlex.

  1. Pre-admission antibiotics for suspected cases of meningococcal disease.The Cochrane database of systematic reviews · 2017
    Pooled it
  2. Article
  3. Restriction-modification systems are required forProceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  4. Article
  5. Restriction-modification systems are required forbioRxiv : the preprint server for biology · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Structure of the virulence-associatedProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  11. Article
  12. Article
  13. Internalization ofMicroorganisms · 2025
    Article
  14. Article
  15. Frontiers in cellular and infection microbiology · 2025
    Review
  16. Review
  17. Article
  18. Review
  19. Interaction ofFrontiers in cellular and infection microbiology · 2024
    Article
  20. Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Darryl J HillDepartment of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, UK. darryl.j.hill@bristol.ac.uk
Natalie J Griffiths
Elena Borodina
Mumtaz Virji
University of Bristol · GB

Funding

Medical Research CouncilWellcome Trust
6 · The paper itself

Abstract

The human species is the only natural host of Neisseria meningitidis, an important cause of bacterial meningitis globally, and, despite its association with devastating diseases, N. meningitidis is a commensal organism found frequently in the respiratory tract of healthy individuals. To date, antibiotic resistance is relatively uncommon in N. meningitidis isolates but, due to the rapid onset of disease in susceptible hosts, the mortality rate remains approx. 10%. Additionally, patients who survive meningococcal disease often endure numerous debilitating sequelae. N. meningitidis strains are classified primarily into serogroups based on the type of polysaccharide capsule expressed. In total, 13 serogroups have been described; however, the majority of disease is caused by strains belonging to one of only five serogroups. Although vaccines have been developed against some of these, a universal meningococcal vaccine remains a challenge due to successful immune evasion strategies of the organism, including mimicry of host structures as well as frequent antigenic variation. N. meningitidis express a range of virulence factors including capsular polysaccharide, lipopolysaccharide and a number of surface-expressed adhesive proteins. Variation of these surface structures is necessary for meningococci to evade killing by host defence mechanisms. Nonetheless, adhesion to host cells and tissues needs to be maintained to enable colonization and ensure bacterial survival in the niche. The aims of the present review are to provide a brief outline of meningococcal carriage, disease and burden to society. With this background, we discuss several bacterial strategies that may enable its survival in the human respiratory tract during colonization and in the blood during infection. We also examine several known meningococcal adhesion mechanisms and conclude with a section on the potential processes that may operate in vivo as meningococci progress from the respiratory niche through the blood to reach the central nervous system.

Indexed as

Carrier StateHost-Pathogen InteractionsHumansMeningesMeningococcal InfectionsNasopharynxNeisseria meningitidisVirulence

Identifiers

PMID20132098
PMCPMC2830671
OpenAlexW2269583392

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.